ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Pilot study of intratonsillar immunotherapy for timothy grass pollen.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergen-specific immunotherapy (AIT) is a treatment for upper airway allergy that is resistant to optimal symptomatic management. Traditionally, it is administered via repeated subcutaneous injections (subcutaneous immunotherapy, SCIT) or daily sublingual tablets/drops (sublingual immunotherapy, SLIT) for 3–5 years. Direct allergen exposure has also been attempted through intralymphatic immunotherapy (ILIT) via injections into inguinal lymph nodes.
objectiveTo evaluate the clinical and immunological effects of intratonsillar allergen immunotherapy for timothy grass pollen allergy.
methodsThis uncontrolled, prospective, cross-sectional, pilot study included 12 patients with allergic rhinoconjunctivitis to timothy grass pollen, refractory to symptomatic treatment. Each patient received a dose of 1 mL 10,000 SQ-U standardized, aluminum hydroxide-adsorbed depot grass pollen extract (Alutard, ALK-Abelló, Denmark) for SCIT at four-week intervals. Follow-up was conducted 18 months after the final injection.
resultsDuring the first two injections, 7 out of 12 patients developed systemic adverse reactions within minutes, including generalized itching, edema with rashes, tiredness, and mild dyspnea, all resolving spontaneously within two hours without epinephrine administration. Patients reported significant symptom improvement, including reduced nasal congestion, rhinorrhea, sneezing, mouth breathing, and ocular itching. Immunologically, the antibody responses to timothy pollen (IgE and IgG4) showed similarities to patterns previously described for SLIT, SCIT and ILIT.
conclusionsIntratonsillar depot grass pollen extract injections improved symptoms of timothy-induced allergic rhinoconjunctivitis. It also induced immunological alterations characteristic for allergen-specific immunotherapy. To our knowledge, this is the first study to report the intratonsillar administration of AIT for grass pollen allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.